2014 Vanderbilt GSC 3MT Finalist: Dikshya Bastakoty - Cardiovascular cell therapy 2014 Vanderbilt GSC 3MT Finalist: Dikshya Bastakoty - Cardiovascular cell therapy: teaching stem cells to fix the broken heart. By: VanderbiltGSC … Continue reading →

London, UK (PRWEB) June 24, 2014 Over the past 5 years, the world cancer cell therapy market witnessed strong growth. Furthermore, this market is expected to keep on following an upward trend in the years ahead, driven by the increasing cancer incidence worldwide, rising adoption of novel drugs, high unmet needs along with the continuously enhancing popularity of cell therapy in the sphere of cancer treatment. A number of technologies and products for cancer treatment based on cell-therapies, which are currently in the R&D pipeline, are predicted to enter the market in the next five years. At present, the US holds the lions share of the world cancer cell therapy market. Nevertheless, the markets future growth globally is likely to be spurred by the developing countries, where the incidence rates of cancer are very high. Adaptimmune, Apceth, Argos Therapeutics, Celgene Cellular Therapeutics, Cellerant Therapeutics, Immunicum, Innate Pharma, Innocell Corporation, Kite Pharma and Takara Bio are among the top companies operating in the worldwide cancer cell therapy market. New research report Cancer Cell Therapy Market & Pipeline Insight elaborated by Kuick Research is now available at MarketPublishers.com. Report Details: Title: Cancer Cell Therapy Market & Pipeline Insight Published: June, 2013 Pages: … Continue reading →

GOSSELIES, Belgium, June 25, 2014 /PRNewswire/ -- Minimally invasive bone forming product ALLOBin Phase I/IIa trial for delayed union fracture Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, today announces that the first patient has been treated with its novel allogeneic osteoblastic (bone-forming) cell therapy product ALLOB in its phase I/IIa study for the treatment of delayed union fractures. ALLOB is the first ever allogeneic differentiated[1] osteoblastic cell therapy product developed for the treatment of orthopaedic conditions. Allogeneic cell therapy involves the harvesting of cells from a healthy, universal donor, rather than from the patient being treated. ALLOB has shown safety and efficacy in preclinical studies and does not require any immunosuppressive side therapy. ALLOB has the potential to become a first-line treatment for impaired fracture healing, thanks to its minimally invasive percutaneous administration. Delayed union fractures, defined by the absence of fracture healing after 3 months, affect around 600,000 to 900,000 new patients a year in Europe and the US. The current standard of care for delayed union fractures involves highly invasive surgery, which takes up to several hours followed by a long hospitalization. By contrast, this first administration … Continue reading →